|
1
|
Escudier B: Advanced renal cell carcinoma:
Current and emerging management strategies. Drugs. 67:1257–1264.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wuthrick EJ, Kamrava M, Curran WJ Jr,
Werner-Wasik M, Camphausen KA, Hyslop T, Axelrod R, Andrews DW,
Glass J, Machtay M, et al: A phase 1b trial of the combination of
the antiangiogenic agent sunitinib and radiation therapy for
patients with primary and metastatic central nervous system
malignancies. Cancer. 117:5548–5559. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Albiges L, Oudard S, Negrier S, Caty A,
Gravis G, Joly F, Duclos B, Geoffrois L, Rolland F, Guillot A, et
al: Complete remission with tyrosine kinase inhibitors in renal
cell carcinoma. J Clin Oncol. 30:482–487. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang HP, Takayama K, Su B, Jiao XD, Li R
and Wang JJ: Effect of sunitinib combined with ionizing radiation
on endothelial cells. J Radiat Res (Tokyo). 52:1–8. 2011.
View Article : Google Scholar
|
|
5
|
Walsh L, Stanfield JL, Cho LC, Chang CH,
Forster K, Kabbani W, Cadeddu JA, Hsieh JT, Choy H, Timmerman R, et
al: Efficacy of ablative high-dose-per-fraction radiation for
implanted human renal cell cancer in a nude mouse model. Eur Urol.
50:795–800; discussion 800. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pellerin O, Medioni J, Vulser C, Déan C,
Oudard S and Sapoval M: Management of painful pelvic bone
metastasis of renal cell carcinoma using embolization,
radio-frequency ablation, and cementoplasty: A prospective
evaluation of efficacy and safety. Cardiovasc Intervent Radiol.
37:730–736. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niibe Y and Hayakawa K: Oligometastases
and oligo-recurrence: The new era of cancer therapy. Jpn J Clin
Oncol. 40:107–111. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili
R, Bjarnason GA, et al: Overall survival and updated results for
sunitinib compared with interferon alfa in patients with metastatic
renal cell carcinoma. J Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsui KH, Shvarts O, Smith RB, Figlin RA,
deKernion JB and Belldegrun A: Prognostic indicators for renal cell
carcinoma: A multivariate analysis of 643 patients using the
revised 1997 TNM staging criteria. J Urol. 163:1090–1095; quiz
1295. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Daliani DD, Tannir NM, Papandreou CN, Wang
X, Swisher S, Wood CG, Swanson DA, Logothetis CJ and Jonasch E:
Prospective assessment of systemic therapy followed by surgical
removal of metastases in selected patients with renal cell
carcinoma. BJU Int. 104:456–460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
DeMeerleer G, Khoo V, Escudier B, Joniau
S, Bossi A, Ost P, Briganti A, Fonteyne V, Van Vulpen M, Lumen N,
et al: Radiotherapy for renal-cell carcinoma. Lancet Oncol.
15:e170–e177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Escudier B and Kataja V: ESMO Guidelines
Working Group: Renal cell carcinoma: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21
(Suppl 5):v137–v139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al: TARGET Study Group: Sorafenib in advanced clear-cell
renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stinauer MA, Kavanagh BD, Schefter TE,
Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M and
Raben D: Stereotactic body radiation therapy for melanoma and renal
cell carcinoma: Impact of single fraction equivalent dose on local
control. Radiat Oncol. 6:342011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Motzer RJ, Mazumdar M, Bacik J, Berg W,
Amsterdam A and Ferrara J: Survival and prognostic stratification
of 670 patients with advanced renal cell carcinoma. J Clin Oncol.
17:2530–2540. 1999.PubMed/NCBI
|
|
16
|
Russo P, Jang TL, Pettus JA, Huang WC,
Eggener SE, O'Brien MF, Karellas ME, Karanikolas NT and Kagiwada
MA: Survival rates after resection for localized kidney cancer:
1989 to 2004. Cancer. 113:84–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pantuck AJ, Zisman A and Belldegrun AS:
The changing natural history of renal cell carcinoma. J Urol.
166:1611–1623. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zelefsky MJ, Greco C, Motzer R, Magsanoc
JM, Pei X, Lovelock M, Mechalakos J, Zatcky J, Fuks Z and Yamada Y:
Tumor control outcomes after hypofractionated and single-dose
stereotactic image-guided intensity-modulated radiotherapy for
extracranial metastases from renal cell carcinoma. Int J Radiat
Oncol Biol Phys. 82:1744–1748. 2012. View Article : Google Scholar : PubMed/NCBI
|
